Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

Lexaria Bioscience (LEXX) announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide rodent biodistribution study. The ...

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

LifeVantage (LFVN) announced the completion of an international in vitro cell study that investigated the effects of its international ...

Kerry, a global business in taste and nutrition, has outlined five distinct consumer segments among those who consume GLP-1s, each with unique preferences and needs, providing a framework for future ...

In this article, we are going to take a look at where Global Partners LP (NYSE:GLP) stands against other oil & gas stocks that are skyrocketing so far in 2025. The oil & gas sector has ...

Josh Gad has opened up for the first time about using GLP-1 medication for weight loss and his seesaw experience with the positive and negative side effects. The actor and "Frozen" star spoke with ...

The GLP-1 Analogues Market was valued at approximately USD 37 Billion in 2023 and is expected to grow at a substantial CAGR of around 28% during the forecast period (2024-2032) owing to the rising ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.